[Pharmacoeconomic analysis of dabigatran etexilate effectiveness in patients with nonvalvular atrial fibrillation]

MeSH terms

• Anticoagulants / economics
• Anticoagulants / therapeutic use
• Aspirin* / economics
• Aspirin* / therapeutic use
• Atrial Fibrillation* / complications
• Atrial Fibrillation* / economics
• Benzimidazoles* / economics
• Benzimidazoles* / therapeutic use
• Blood Coagulation / drug effects
• Blood Coagulation Tests / methods
• Clopidogrel
• Costs and Cost Analysis / methods
• Costs and Cost Analysis / statistics & numerical data
• Dabigatran
• Humans
• Insurance, Pharmaceutical Services / statistics & numerical data
• Models, Statistical*
• Outcome and Process Assessment, Health Care / methods
• Outcome and Process Assessment, Health Care / statistics & numerical data
• Pyridines* / economics
• Pyridines* / therapeutic use
• Russia
• Thromboembolism* / blood
• Thromboembolism* / drug therapy
• Thromboembolism* / economics
• Thromboembolism* / etiology
• Ticlopidine / administration & dosage
• Ticlopidine / analogs & derivatives*
• Ticlopidine / economics